Bizarre Patents
Neuroimaging as a Marketing Tool
Neuroimaging as a means for validating whether a stimulus such as advertisement, communication, or product evokes a certain mental response such as emotion, preference, or memory, or to predict the consequences of the stimulus on later behavior such as consumption or purchasing.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7459295 | Fibrinogen-based tissue adhesive containing an elastase inhibitor The present invention provides a fibrinogen-based tissue adhesive which contains an elastase inhibitor. ... | 12/02/2008 |
| 7279161 | Factor IX/factor IXa activating antibodies and antibody derivatives An antibody or antibody derivative against factor IX/activated factor IX (FIXa) which increases the procoagulant activity of FIXa. ... | 10/09/2007 |
| 7241603 | Method for producing a preparation based on fibrinogen and fibronectin as well as protein compositions obtainable according to this method A method for producing protein compositions comprising fibrinogen and fibronectin is disclosed, wherein a fibrinogen and fibronectin-containing starting solution is treated with a precipitating composition which comprises two different components that modify the sol... | 07/10/2007 |
| 7220569 | Nucleic acids encoding factor X analogues having a modified protease cleavage site Nucleic acids encoding factor X analogues are provided that have a modification in the region of the natural Factor Xa activation cleavage site. The modification results in a processing site for a protease not naturally cleaving in this region of the Factor X sequen... | 05/22/2007 |
| 7094574 | Recombinant cell clones having increased stability and methods of making and using the same Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recom... | 08/22/2006 |
| 7091325 | Fibrin/fibrinogen-binding conjugate A fibrin/fibrinogen binding conjugate for forming a depot for the sustained release of a pharmaceutically active substance from a fibrin clot. The conjugate comprises a fibrin/fibrinogen binding moiety bound to a pharmaceutically active substance either directly or ... | 08/15/2006 |
| 7091015 | Fibrinogen-based tissue adhesive The present invention provides a fibrinogen-based tissue adhesive which contains an elastase inhibitor. ... | 08/15/2006 |
| 7033590 | Factor IX/factor IXa activating antibodies and antibody derivatives An antibody or antibody derivative against factor IX/activated factor IX (FIXa) which increases the procoagulant activity of FIXa. ... | 04/25/2006 |
| 7005502 | Pharmaceutical preparation comprising vWF propeptide Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWf propeptide as well as a method for producing such a prepartion. ... | 02/28/2006 |
| 6974792 | Alpha 1-antitrypsin preparation as well as a method for producing the same A native, chromatographically purified α1-AT preparation having a purity of at least 0.7 PU/mg protein and a relative plasma α1-AT activity of at least 120% is disclosed. The ratio of active to inactive α1-AT is higher than in plasma. Furthermore, a method... | 12/13/2005 |
| 6958322 | Factor X analog with an improved ability to be activated This invention describes a factor Xa analog which has a substitution of a minimum of one of the amino acid between Glu226 and Arg234 and possibly Ile235, relative to the amino acid numbering according to FIG. 1, a preparation containing the activated form of ... | 10/25/2005 |
| 6953837 | Factor VIII/vWF complexes and compositions There is disclosed a method of recovering factor VIII/vWF-complex which is characterized in that factor VIII/vWF-complex from a protein solution is bound to a cation exchanger and is recovered by step-wise elution of factor VIII/vWF-complex, which particularly conta... | 10/11/2005 |
| 6936441 | Recombinant cell clones having increased stability and methods of making and using the same Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recom... | 08/30/2005 |
| 6926894 | Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV (SEQ ID NO: 1), vWF cleaving complexes and methods for their production. ... | 08/09/2005 |
| 6924151 | Stable factor VIII/vWF-complex There are disclosed a stable factor VIII/vWF-complex, particularly comprising high-molecular vWF multimers, being free from low-molecular vWF molecules and from proteolytic vWF degradation products, as well as a method of producing this complex. ... | 08/02/2005 |
| 6905846 | Nucleic acids encoding factor X deletion mutants and analogues thereof Nucleic acids encoding factor XΔ analogues having a deletion of amino acids Arg180 to Arg234 and a modification in the region of the amino acid sequence between Gly173 and Arg 179 are provided. ... | 06/14/2005 |
| 6831159 | Method for purifying factor VIII/vWF company by cation-exchange chromatography Methods for recovering factor VIII/vWF-complex that involve binding factor VIII/vWF-complex from a protein solution to a cation exchanger and recovering factor VIII/vWF-complex by step-wise elution are disclosed. The recovered complex contains high-molecular vWF mul... | 12/14/2004 |
| 6777390 | Stable blood coagulation inhibitor-free factor vii preparation and method for preparing same Stable pharmaceutical preparations containing blood coagulation Factor VII is disclosed. The pharmaceutical preparations containing blood coagulation Factor VII are free of coagulation inhibitors and are stable over a wide range of environmental conditions. Also pro... | 08/17/2004 |
| 6713453 | Fibrin/fibrinogen-binding conjugate A fibrin/fibrinogen binding conjugate for forming a depot for the sustained release of a pharmaceutically active substance from a fibrin clot. The conjugate comprises a fibrin/fibrinogen binding moiety bound to a pharmaceutically active substance either directly or ... | 03/30/2004 |
| 6670116 | Methods for the detection, quantification and differentiation of infectious versus non-infectious pathogens in a sample Methods are disclosed that permit pathogenic agent detection and differentiation between infectious and non-infectious forms. Specifically, the present invention provides for pathogenic agent detection using nucleic acid amplification and detection techni... | 12/30/2003 |
| 6649339 | Method for producing a quality assured biological sample and composition containing the same A method for producing a pool of biological samples that is quality assured with respect to the load with microorganisms, using a nucleic acid amplification method, in which a screening pool is tested with a high sensitivity nucleic acid amplification met... | 11/18/2003 |
| 6649162 | Hemostatic sponge based on collagen The invention relates to a hemostatic sponge based on collagen and an activator or proactivator of blood coagulation homogeneously distributed therein, which is dried and contains a water content of at least 2%, preferably in the range of 2 to 25%, more p... | 11/18/2003 |
| 6646108 | Process for isolating IgG and IgA A method for the separation of IgG and IgA from an immunoglobulin-containing starting material is described, whereby the method is characterized in that (i) IgG and optionally IgA are adsorbed to a solid inorganic carrier material, (ii) IgA is isolated fr... | 11/11/2003 |
| 6620125 | Method and device for mixing and applying components of differing viscosities A method and a device for mixing at least two liquid components of different viscosities of a multi-component material, such as a tissue adhesive, during application thereof, are disclosed, the components being pressed out of separate containers, mixed, a... | 09/16/2003 |
| 6605222 | Method for producing a factor VIII/von Willebrand factor complex The invention relates to a method for the production of factor VIII:C/von Willebrand factor complex from plasma or a plasma fraction by chromatography in a cation exchanger, wherein the factor VIII:C/von Willebrand factor complex is obtained with at least... | 08/12/2003 |
| 6596526 | Furin polypeptides with improved characteristics The present invention comprises a furin polypeptide having a modified amino acid sequence between the middle, homo-B-domain and the transmembrane domain compared to wild-type furin which retains proteolytic activity but is secreted at lower levels in cell... | 07/22/2003 |
| 6579723 | Method of recovering highly purified vWF or factor VIII/vWF-complex A method for purifying factor VIII/vWF complex or free vWF by immunoaffinity chromatography in a form suitable for use as a medicament. Factor VIII/vWF complex or free vWF is recovered from an immunoaffinity adsorbent by using an eluting agent containing ... | 06/17/2003 |
| 6579537 | Method for producing fibronectin and fibrinogen compositions using a polyalkylene glycol and glycine or ଲ-alanine A method of producing a pharmaceutical preparation comprising fibronectin and fibrinogen is disclosed. The method involves admixing into a starting solution of fibrinogen and fibronectin, in a single step, a precipitating composition comprising a polyalky... | 06/17/2003 |
| 6573071 | Factor X analogues with a modified protease cleavage site Factor X analogues having a modification in the region of the natural Factor Xa activation cleavage site, said modification representing a processing site of a protease not naturally cleaving in this region of the Factor X sequence, preparations containin... | 06/03/2003 |
| 6562598 | Factor X deletion mutants and analogues thereof Factor XƊ analogues are provided, as well as pharmaceutical preparations containing such analogues and methods of preparing such analogues. The factor XƊ analogues have a deletion of the amino acids Arg180 to Arg234 and a modification in the region of t... | 05/13/2003 |
| 6548729 | Fibrin sponge The invention relates to a fibrin sponge comprising a residual moisture content of at least 3%, preferably of 3 to 35%, in particular 10 to 20%, and preferably containing a blood clotting activator or proactivator, a method of preparing this fibrin sponge... | 04/15/2003 |
| 6506365 | Fibrin/fibrinogen binding conjugate The invention relates to fibrin/fibrinogen binding conjugate comprising a fibrin/fibrinogen binding moiety, a substance capturing moiety capable of reversibly binding to a pharmaceutically active substance, and a pharmaceutically active substance, wherein the fibri... | 01/14/2003 |
| 6475725 | Recombinant cell clones having increased stability and methods of making and using the same Disclosed are stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of prepar... | 11/05/2002 |
| 6465624 | Purification of von-Willebrand factor by cation exchanger chromatography Disclosed are a method of recovering vWF in which vWF at a low salt concentration is bound to a cation exchanger and vWF having a high specific activity is recovered by fractionated elution, as well as a preparation having purified vWF obtainable by this ... | 10/15/2002 |
| 6465170 | Method for depleting viral and molecular pathogens in a biological material A method for depleting viral and molecular pathogens in a biological material containing one or several biological substances to be recovered is disclosed, wherein the biological material is admixed with an organic solvent, the solvent-admixed biological ... | 10/15/2002 |
| 6414125 | Method of chromatographically purifying or fractionating, respectively, von Willebrand factor from a VWF-containing starting material Disclosed is a method of chromatographically purifying or fractionating, respectively, von Willebrand factor (vWF) from a vWF-containing starting material, comprising the following steps: adsorbing the vWF from the starting material on avid collagen immobilize... | 07/02/2002 |
| 6403556 | Pharmaceutical preparation containing protein C and a thrombolytically active substance A pharmaceutical preparation contains protein C and a thrombolytically active substance that does not activate protein C. This preparation prevents reocclusion usually occurring in the course of thrombolysis therapy.... | 06/11/2002 |
| 6395880 | Method for purification of antithrombin III using an anion exchanger A method of purifying antithrombin III (AT III) from a starting material containing an AT III/heparin complex or an AT III/heparinoid complex is disclosed. First, the method comprises adsorbing the AT III/heparin complex or the AT III/heparinoid complex o... | 05/28/2002 |
| 6372223 | Influenza virus vaccine composition This invention describes an influenza virus vaccine containing an influenza virus antigen obtained from a cell culture, with an influenza virus antigen content between 1 μg and 5 μg per dose and aluminum as an adjuvant as well as a method for its prepar... | 04/16/2002 |
| 6358918 | Preparation comprising thiol-group-containing proteins There is disclosed a stable, virus-safe, pharmaceutical preparation comprising thiol-group-containing proteins which are heat-treated and processed such that at least 40% of the thiol groups are capable of being nitrosated, a method of preparing such prep... | 03/19/2002 |
